Literature DB >> 26215749

True targeting-derived prostate biopsy: HistoScanning™ remained inadequate despite advanced technical efforts.

Jonas Schiffmann1, Gisa Mehring2, Pierre Tennstedt3, Lukas Manka4, Katharina Boehm3,5, Sami-Ramzi Leyh-Bannurah2, Pierre I Karakiewicz5,6, Peter Hammerer4, Markus Graefen3, Georg Salomon3.   

Abstract

PURPOSE: To verify the reliability of HistoScanning™-based, true targeting (TT)-derived prostate biopsy.
METHODS: We relied on 40 patients suspicious for prostate cancer who underwent standard and TT-derived prostate biopsy. Sensitivity, specificity, positive predictive value, negative predictive value and the area under the curve (AUC) were assessed for the prediction of biopsy results per octant by HistoScanning™, using different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml).
RESULTS: Overall, 319 octants were analyzed. Of those, 64 (20.1 %) harbored prostate cancer. According to different HistoScanning™ signal volume cutoffs (>0, >0.2 and >0.5 ml), the AUCs for predicting biopsy results were: 0.51, 0.51 and 0.53, respectively. Similarly, the sensitivity, specificity, positive predictive and negative predictive values were: 20.7, 78.2, 17.4 and 81.6 %; 20.7, 82.0, 20.3 and 82.3 %; and 12.1, 94.6, 33.3 and 82.9 %, respectively.
CONCLUSIONS: Prediction of biopsy results based on HistoScanning™ signals and TT-derived biopsies was unreliable. Moreover, the AUC of TT-derived biopsies was low and did not improve when additional signal volume cutoffs were applied (>0.2 and >0.5 ml). We cannot recommend a variation of well-established biopsy standards or reduction in biopsy cores based on HistoScanning™ signals.

Entities:  

Keywords:  HistoScanning™; Imaging; Prostate biopsy; Prostate cancer; True targeting; Ultrasound

Mesh:

Year:  2015        PMID: 26215749     DOI: 10.1007/s00345-015-1637-x

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  11 in total

1.  Prostate histoscanning true targeting guided prostate biopsy: initial clinical experience.

Authors:  Arjun Sivaraman; Rafael Sanchez-Salas; Eric Barret; Petr Macek; Pierre Validire; Marc Galiano; Francois Rozet; Xavier Cathelineau
Journal:  World J Urol       Date:  2014-12-12       Impact factor: 4.226

Review 2.  Controversial evidence for the use of HistoScanning™ in the detection of prostate cancer.

Authors:  Jonas Schiffmann; Lukas Manka; Katharina Boehm; Sami-Ramzi Leyh-Bannurah; Pierre I Karakiewicz; Markus Graefen; Peter Hammerer; Georg Salomon
Journal:  World J Urol       Date:  2015-04-10       Impact factor: 4.226

3.  Histoscanning has low sensitivity and specificity for seminal vesicle invasion.

Authors:  Jonas Schiffmann; Burkhard Beyer; Johannes Fischer; Pierre Tennstedt; Katharina Boehm; Uwe Michl; Markus Graefen; Georg Salomon
Journal:  Urology       Date:  2014-10-24       Impact factor: 2.649

4.  Computer-aided ultrasonography (HistoScanning): a novel technology for locating and characterizing prostate cancer.

Authors:  Johan Braeckman; Philippe Autier; Christian Garbar; Miriam Pipeleers Marichal; Cristina Soviany; Rina Nir; Dror Nir; Dirk Michielsen; Harry Bleiberg; Lars Egevad; Mark Emberton
Journal:  BJU Int       Date:  2007-10-08       Impact factor: 5.588

5.  Does HistoScanning™ predict positive results in prostate biopsy? A retrospective analysis of 1,188 sextants of the prostate.

Authors:  J Schiffmann; P Tennstedt; J Fischer; Zhe Tian; B Beyer; K Boehm; M Sun; G Gandaglia; U Michl; M Graefen; G Salomon
Journal:  World J Urol       Date:  2014-05-29       Impact factor: 4.226

6.  Utility of Histoscanning™ prior to prostate biopsy for the diagnosis of prostate adenocarcinoma.

Authors:  C Núñez-Mora; J M García-Mediero; P Patiño; C Orellana; A Garrido; A Rojo; D Rendón
Journal:  Actas Urol Esp       Date:  2013-03-16       Impact factor: 0.994

7.  Prostate histoscanning in clinically localized biopsy proven prostate cancer: an accuracy study.

Authors:  Petr Macek; Eric Barret; Rafael Sanchez-Salas; Marc Galiano; Francois Rozet; Youness Ahallal; Joseph M Gaya; Matthieu Durant; Laurent Mascle; Camilo Giedelman; Luca Lunelli; Pierre Validire; Marcel Nesvadba; Xavier Cathelineau
Journal:  J Endourol       Date:  2013-12-26       Impact factor: 2.942

8.  The accuracy of transrectal ultrasonography supplemented with computer-aided ultrasonography for detecting small prostate cancers.

Authors:  Johan Braeckman; Philippe Autier; Cristina Soviany; Rina Nir; Dror Nir; Dirk Michielsen; Karien Treurnicht; Michael Jarmulowicz; Harry Bleiberg; Senthil Govindaraju; Mark Emberton
Journal:  BJU Int       Date:  2008-08-14       Impact factor: 5.588

9.  Does prostate HistoScanning™ play a role in detecting prostate cancer in routine clinical practice? Results from three independent studies.

Authors:  Saqib Javed; Eliot Chadwick; Albert A Edwards; Sabeena Beveridge; Robert Laing; Simon Bott; Christopher Eden; Stephen Langley
Journal:  BJU Int       Date:  2014-03-20       Impact factor: 5.588

10.  Comparison of prostate cancer volume measured by HistoScanning™ and final histopathological results.

Authors:  J Schiffmann; J Fischer; P Tennstedt; B Beyer; K Böhm; U Michl; M Graefen; G Salomon
Journal:  World J Urol       Date:  2013-11-24       Impact factor: 4.226

View more
  3 in total

Review 1.  HistoScanningTM to Detect and Characterize Prostate Cancer-a Review of Existing Literature.

Authors:  James S Wysock; Alex Xu; Clement Orczyk; Samir S Taneja
Journal:  Curr Urol Rep       Date:  2017-10-24       Impact factor: 3.092

2.  Advanced ultrasound in the diagnosis of prostate cancer.

Authors:  Jean-Michel Correas; Ethan J Halpern; Richard G Barr; Sangeet Ghai; Jochen Walz; Sylvain Bodard; Charles Dariane; Jean de la Rosette
Journal:  World J Urol       Date:  2020-04-18       Impact factor: 4.226

3.  A systematic review and meta-analysis of Histoscanning™ in prostate cancer diagnostics.

Authors:  Andrey Morozov; Vasiliy Kozlov; Juan Gomez Rivas; Jeremy Yuen-Chun Teoh; Evgeniy Bezrukov; Alexander Amosov; Eric Barret; Mark Taratkin; Georg Salomon; Thomas R W Herrmann; Ali Gozen; Dmitry Enikeev
Journal:  World J Urol       Date:  2021-04-07       Impact factor: 4.226

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.